One of its members, FABP4, is reported to be overexpressed in cancers, such as prostate and ovarian cancers (Uehara et al., 2014 ; Gharpure et al., 2018), but it is found to suppress cell proliferation in hepatocellular carcinomas and endometrial cancers (Zhong et al., 2018; Wu et al., 2021). Here, FABP4 is linked to cancer.